Aspen Pharmacare has secured a licensing agreement to enter the GLP-1 agonist market, positioning it for growth in diabetes and obesity treatment solutions.
Aspen secures licensing agreement to enter GLP-1 market
Original Article by Nompilo Goba | Business Day | 30 October 2024
Aspen Pharmacare has secured a licensing agreement to enter the GLP-1 agonist market, positioning it for growth in diabetes and obesity treatment solutions.
More Posts
NHLS Scrambles as Pathology Services Funding Runs Dry
The NHLS is scrambling for new providers after funds for haematology pathology services ran dry, amid an R11.3bn provincial debt
Read more...
Momentum Group Posts Record Earnings
Momentum Group has posted record earnings, with normalised headline earnings up 13% to R7.06bn – beating its R7bn Impact target a year early.
Read more...
Sanlam Writes Down AfroCentric to Nil but Won’t Sell
Sanlam has written its AfroCentric stake down to nil after the Bonitas exit but rules out a sale, betting it can revive the business.
Read more...